	US 12,240,909 B2
	Human antibodies to human interleukin 18 receptor alpha or beta
Sachedv S. Sidhu, Toronto (CA); Donghui Wu, Shanghai (CN); Guohua James Pan, Toronto (CA); Shusu Liu, Shanghai (CN); Shane Miersch, Toronto (CA); and Haiming Huang, Toronto (CA)
Assigned to ShanghaiTech University, Shanghai (CN); and The Governing Council of the University of Toronto, Toronto (CA)
Appl. No. 17/254,248
Filed by ShanghaiTech University, Pudong New Area (CN); and The Governing Council of the University of Toronto, Toronto (CA)
PCT Filed Jun. 19, 2019, PCT No. PCT/CN2019/091936 § 371(c)(1), (2) Date Dec. 18, 2020, PCT Pub. No. WO2019/242655, PCT Pub. Date Dec. 26, 2019.
Claims priority of application No. PCT/CN2018/091780 (WO), filed on Jun. 19, 2018.
Prior Publication US 2024/0262919 A1, Aug. 8, 2024
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2866 (2013.01) [C07K 2317/31 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)]

6 Claims

1. An antibody or antigen-binding fragment thereof having binding specificity to a human interleukin-18 receptor beta (IL-18Rβ) protein, wherein the antibody or fragment thereof comprises a light chain variable region (VL) comprising light chain complementarity determining regions CDRL1, CDRL2, and CDRL3 and a heavy chain variable region (VH) comprising heavy chain complementarity determining regions CDRH1, CDRH2, and CDRH3, and wherein the CDRL1, CDRL2, CDRL3, CDRH1, CDRH2 and CDRH3 comprise the amino acid sequences of SEQ ID NO:45, 46, 333, 74, 346 and 117, respectively.